MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2026.1912138

Медицинская библиотека · Frontiers in endocrinology · 2026

Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes.

Araújo Jéssica S, Boris Natália P, Lopes Fábia Karine de M, Flor Amanda C, Leite Liz Marjorie B F, Linard Lana Lívia P, Bezerra Isabella C, Cavalcante Janio Emanuel A, Tanaka Edson, Sandrini Fabiano, Fernandes Virgínia O, Montenegro Junior Renan M

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Evidence on glucagon-like peptide 1 receptor agonists (GLP-1RAs) in lipodystrophies is limited. We evaluated the effects of liraglutide on metabolic control and satiety in patients with congenital generalized lipodystrophy (CGL).

METHODS

In this case series, patients with CGL received liraglutide 1.8 mg/day for 12 weeks. Metabolic parameters, satiety, and body composition were assessed at baseline, week 12, and after a 12-week post-treatment follow-up (week 24). Liver imaging was performed at baseline and week 12.

RESULTS

Eight patients were enrolled (aged 24-45 years; 75% female), and three discontinued treatment due to gastrointestinal adverse events during the dose-escalation phase. Among the five participants who completed the 12-week intervention, liraglutide significantly reduced HbA1c (median change, -2.5%; p=0.012) and total daily insulin dose (-20%; p=0.042), whereas the reduction in triglyceride levels was not statistically significant. Twelve weeks after liraglutide discontinuation, median HbA1c and body weight increased by 2.2% (p=0.026) and 3.7% (p=0.001), respectively. Triglyceride levels increased in 80% of participants, with a median increase of 421.5 mg/dL (p=0.334). Insulin requirements also increased overall: one participant resumed insulin therapy, while the remaining participants increased their insulin dose by a median of 22% (p=0.024).

CONCLUSIONS

This first study of liraglutide in CGL provides an exploratory signal of improved glycemic control and reduced insulin requirements, but treatment tolerability remains a limitation. Larger, controlled, and longer-term studies are needed to confirm these effects and assess potential benefits on satiety, body composition, and liver disease.

Для цитирования: Araújo Jéssica S, Boris Natália P, Lopes Fábia Karine de M, Flor Amanda C, Leite Liz Marjorie B F, Linard Lana Lívia P, Bezerra Isabella C, Cavalcante Janio Emanuel A, Tanaka Edson, Sandrini Fabiano, Fernandes Virgínia O, Montenegro Junior Renan M. Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes.. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1912138.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.